Works about SORAFENIB

Results: 1690

IL-2-loaded liposomes modified with sorafenib derivative exert a synergistic anti-melanoma effect via improving tumor immune microenvironment and enhancing antiangiogenic activity.

Published in:

Asian Journal of Pharmaceutical Sciences, 2025, v. 20, n. 2, p. 1, doi. 10.1016/j.ajps.2025.101020

By:

Xuan Huang;
Kuerban, Kudelaidi;
Jajun Fan;
Danjie Pan;
Huaning Chen;
Jiayang Liu;
Songna Wang;
Dianwen Ju;
Yi Zhun Zhu;
Jiyong Liu;
Li Ye

Publication type:

Article

Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib for advanced hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (Double-IA-001): a phase II trial.

Published in:

BMC Medicine, 2025, v. 23, n. 1, p. 1, doi. 10.1186/s12916-025-04110-1

By:

Shen, Lujun;
Cao, Fei;
Liu, Ying;
Nuerhashi, Gulijiayina;
Lin, Letao;
Tan, Hontong;
Wen, Chunyong;
Wang, Yujia;
Chen, Shuanggang;
Zou, Hongliang;
Xie, Lin;
Fan, Weijun

Publication type:

Article

EVALUATION OF HEPATOTOXICITY IN PATIENTS EXPOSED TO NEUROMODULATOR AND ANTINEOPLASTIC DRUGS.

Published in:

European Review for Medical & Pharmacological Sciences, 2025, v. 29, n. 4, p. 180

By:

SAMPAIO, V. C.;
COSTA, R. B.;
ALVES, P. H.;
TONIASSO, S. C. C.;
BALDIN, C. P.;
RIEDEL, P. G.;
WAYHS, C. A. Y.;
DIEMEN, T. V.;
JOVELEVITHS, D.

Publication type:

Article

Molecular Dynamics Study of Sorafenib Anti‐Cancer Drug: Inclusion Complex in Amphiphilic Cyclodextrin.

Published in:

Macromolecular Symposia, 2021, v. 395, n. 1, p. 1, doi. 10.1002/masy.202000201

By:

Raffaini, Giuseppina;
Mazzaglia, Antonino;
Catauro, Michelina

Publication type:

Article

RNA-binding protein Dnd1 inhibits epithelial-mesenchymal transition and cancer stem cell-related traits on hepatocellular carcinoma cells.

Published in:

Biotechnology Letters, 2017, v. 39, n. 9, p. 1359, doi. 10.1007/s10529-017-2375-5

By:

Xu, Weiling;
Gong, Fangchao;
Zhang, Ting;
Chi, Baorong;
Wang, Jingyu

Publication type:

Article

Establishment of childhood hepatoblastoma xenografts and evaluation of the anti-tumour effects of anlotinib, oxaliplatin and sorafenib.

Published in:

Pediatric Surgery International, 2022, v. 38, n. 3, p. 465, doi. 10.1007/s00383-021-05043-5

By:

Yang, Dou;
Chen, Feng;
Gong, Dan;
Zeng, Lei;
Xiang, Deng;
He, Yuanqiao;
Chen, Leifeng;
Yan, Jinlong;
Zhang, Shouhua

Publication type:

Article

Development and External Validation of the Munich Sorafenib Evaluation Score for Hepatocellular Carcinoma.

Published in:

Digestive Diseases, 2023, v. 41, n. 2, p. 268, doi. 10.1159/000524336

By:

op den Winkel, Mark;
Nagel, Dorothea;
Seidensticker, Max;
De Toni, Enrico N.;
Merz, Jessica;
op den Winkel, Jan;
Öcal, Osman;
Stecher, Stephanie-Susanne;
Bourhis, Hélène;
Malfertheiner, Peter;
Mayerle, Julia;
Ricke, Jens;
Kolligs, Frank T.

Publication type:

Article

Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review.

Published in:

Digestive Diseases, 2022, v. 40, n. 5, p. 565, doi. 10.1159/000520095

By:

Reiter, Florian P.;
Ben Khaled, Najib;
Ye, Liangtao;
Zhang, Changhua;
Seidensticker, Max;
op den Winkel, Mark;
Denk, Gerald;
Geier, Andreas;
De Toni, Enrico N.

Publication type:

Article

Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience.

Published in:

Digestive Diseases, 2018, v. 36, n. 5, p. 377, doi. 10.1159/000490378

By:

Longo, Larisse;
de Freitas, Laura Bainy Rodrigues;
Santos, Deivid;
Grivicich, Ivana;
Álvares-da-Silva, Mário Reis

Publication type:

Article

Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.

Published in:

Digestive Diseases, 2018, v. 36, n. 1, p. 78, doi. 10.1159/000477578

By:

Labenz, Christian;
Prenosil, Vera;
Koch, Sandra;
Huber, Yvonne;
Marquardt, Jens U.;
Schattenberg, Jörn M.;
Galle, Peter R.;
Weinmann, Arndt;
Wörns, Marcus-Alexander

Publication type:

Article

Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.

Published in:

Digestive Diseases, 2017, v. 35, n. 6, p. 78, doi. 10.1159/000477578

By:

Labenz, Christian;
Prenosil, Vera;
Koch, Sandra;
Huber, Yvonne;
Marquardt, Jens U.;
Schattenberg, Jörn M.;
Galle, Peter R.;
Weinmann, Arndt;
Wörns, Marcus-Alexander

Publication type:

Article

Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.

Published in:

Digestive Diseases, 2017, v. 35, n. 6, p. 611, doi. 10.1159/000480257

By:

Kazuomi Ueshima;
Naoshi Nishida;
Masatoshi Kudo

Publication type:

Article

Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.

Published in:

Digestive Diseases, 2017, v. 35, n. 6, p. 602, doi. 10.1159/000480256

By:

Atsushi Hiraoka;
Takashi Kumada;
Masatoshi Kudo;
Masashi Hirooka;
Yohei Koizumi;
Yoichi Hiasa;
Kazuto Tajiri;
Hidenori Toyoda;
Toshifumi Tada;
Hironori Ochi;
Koji Joko;
Noritomo Shimada;
Akihiro Deguchi;
Toru Ishikawa;
Michitaka Imai;
Kunihiko Tsuji;
Kojiro Michitaka

Publication type:

Article

Treatment of liver cancer cells with ethyl acetate extract of Crithmum maritimum permits reducing sorafenib dose and toxicity maintaining its efficacy.

Published in:

Journal of Pharmacy & Pharmacology, 2021, v. 73, n. 10, p. 1369, doi. 10.1093/jpp/rgab070

By:

Gnocchi, Davide;
Castellaneta, Francesca;
Cesari, Gianluigi;
Fiore, Giorgio;
Sabbà, Carlo;
Mazzocca, Antonio

Publication type:

Article

Sorafenib suppresses proliferation rate of fibroblast-like synoviocytes through the arrest of cell cycle in experimental adjuvant arthritis.

Published in:

Journal of Pharmacy & Pharmacology, 2021, v. 73, n. 1, p. 32, doi. 10.1093/jpp/rgaa053

By:

YongFang Gong;
TianYu Huang;
QiRui Yu;
Biao Liu;
Jing Wang;
ZhenHuan Wang;
XueYing Huang

Publication type:

Article

The Prognostic Significance of ACLR and HALP Scores in Hepatocellular Carcinoma Patients Treated with Sorafenib.

Published in:

Zagazig University Medical Journal, 2024, v. 30, n. 6, p. 2533, doi. 10.21608/zumj.2024.295419.3431

By:

Mohamed, Amrallah A.;
Shabana, Marwa Abo;
Mohamed, Yara Naser;
Bakry, Adel

Publication type:

Article

Impact of Prognostic Nutritional Index and Systemic Immune-Inflammation Index on the Clinical Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.

Published in:

Zagazig University Medical Journal, 2023, v. 29, n. 2, p. 650, doi. 10.21608/zumj.2022.141934.2577

By:

Waley, Ahmad Barakat;
Haggag, Rasha;
Ahmed Barakat, Amir Abd-elhameed;
Rashied, Hanaa Ahmed;
Abdul-Saboor, Ahmed;
Esawy, Marwa Mohammed;
Orban, Yasser Ali;
Bakry, Adel

Publication type:

Article

Long noncoding RNA CASC11 suppresses sorafenib-triggered ferroptosis via stabilizing SLC7A11 mRNA in hepatocellular carcinoma cells.

Published in:

Discover Oncology, 2023, v. 14, n. 1, p. 1, doi. 10.1007/s12672-023-00761-9

By:

Chen, Fei;
Wang, Liang

Publication type:

Article

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study.

Published in:

NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-022-00341-0

By:

Nelson, Blessie Elizabeth;
Roszik, Jason;
Janku, Filip;
Hong, David S.;
Kato, Shumei;
Naing, Aung;
Piha-Paul, Sarina;
Fu, Siqing;
Tsimberidou, Apostolia;
Cabanillas, Maria;
Busaidy, Naifa Lamki;
Javle, Milind;
Byers, Lauren Averett;
Heymach, John V.;
Meric-Bernstam, Funda;
Subbiah, Vivek

Publication type:

Article

Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells.

Published in:

Non-Coding RNA, 2022, v. 8, n. 4, p. 61, doi. 10.3390/ncrna8040061

By:

Lu, Qingchun;
Xin, Mingyang;
Guo, Qian;
Rothberg, Brad S.;
Gamero, Ana M.;
Yang, Ling

Publication type:

Article

LARP4B promotes hepatocellular carcinoma progression and impairs sorafenib efficacy by activating SPINK1-mediated EGFR pathway.

Published in:

Cell Death Discovery, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41420-024-01985-6

By:

Wang, Chuanxu;
Dong, Rui;
Yang, Feicheng;
Zheng, Lu;
Liu, Yingling;
Yan, Yue;
Zhang, Mengjie;
Ni, Bing;
Li, Jing

Publication type:

Article

MCL1 inhibition: a promising approach to augment the efficacy of sorafenib in NSCLC through ferroptosis induction.

Published in:

Cell Death Discovery, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41420-024-01908-5

By:

Huang, Chao-Yuan;
Chen, Li-Ju;
Chen, Chi-Shuo;
Wang, Cheng-Yi;
Hong, Shiao-Ya

Publication type:

Article

Engineered small extracellular vesicles loaded with miR-654-5p promote ferroptosis by targeting HSPB1 to alleviate sorafenib resistance in hepatocellular carcinoma.

Published in:

Cell Death Discovery, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41420-023-01660-2

By:

Sun, Jiao;
Liu, Qi;
Jiang, Yanfang;
Cai, Zhihui;
Liu, Hui;
Zuo, Huaiwen

Publication type:

Article

PLEKHG5 is stabilized by HDAC2-related deacetylation and confers sorafenib resistance in hepatocellular carcinoma.

Published in:

Cell Death Discovery, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41420-023-01469-z

By:

Sha, Yu;
Pan, Mingang;
Chen, Yunmeng;
Qiao, Liangjun;
Zhou, Hengyu;
Liu, Dina;
Zhang, Wenlu;
Wang, Kai;
Huang, Luyi;
Tang, Ni;
Qiu, Jianguo;
Huang, Ailong;
Xia, Jie

Publication type:

Article

Boric Acid Treatment Strengthens the Cytotoxic Effect of Sorafenib on Triple Negative Breast Cancer Cell Lines.

Published in:

Celal Bayar University Journal of Science, 2023, v. 19, n. 2, p. 137, doi. 10.18466/cbayarfbe.1201068

By:

Kahraman, Erkan;
Göker, Erdem

Publication type:

Article

Syringodium isoetifolium Fosters an Antioxidant Defense System, Modulates Glycolytic Enzymes and Protects Membrane Integrity in DEN-induced Hepatocellular Carcinoma in Albino Wistar Rats.

Published in:

Indian Journal of Pharmaceutical Education & Research, 2023, v. 57, p. S690, doi. 10.5530/ijper.57.3s.78

By:

Kavitha, Dhanaraju;
Padmini, Ramakrishnan;
Dhanaraju, Magharla Dasaratha;
Gopi, Chandravadivelu;
Thiyagarajan, Deepan;
Veeramaneni, Alekkhya

Publication type:

Article

QUANTITATIVE ANALYSIS OF SORAFENIB AND NILOTINIB IN HUMAN PLASMA BY SPE-LC-MS.

Published in:

Farmacia, 2023, v. 71, n. 5, p. 1024, doi. 10.31925/farmacia.2023.5.17

By:

POPESCU, MONICA DENISA ELENA;
MANDA, COSTEL-VALENTIN;
CALUCICĂ, DANIELA MARIA;
GĂMAN, AMELIA MARIA;
NEAMȚU, JOHNY;
BIȚĂ, ANDREI;
MATEESCU, OLIVIA GAROFIȚA;
NEAMȚU, SIMONA-DANIELA;
RĂILEANU, ȘTEFAN;
STANCA, LILIANA;
CROITORU, OCTAVIAN

Publication type:

Article

Disparities in Access to Sorafenib in Communities with Low Socioeconomic Status.

Published in:

Journal of Health Care for the Poor & Underserved, 2018, v. 29, n. 3, p. 1123, doi. 10.1353/hpu.2018.0083

By:

Sarpel, Umut;
Heskel, Marina;
Spivack, John Henry;
Feferman, Yael;
Ang, Celina;
Gany, Francesca

Publication type:

Article

Synthesis and anti-tumor activity of asiatic acid derivatives targeting VEGFR.

Published in:

Journal of Asian Natural Products Research, 2023, v. 25, n. 12, p. 1205, doi. 10.1080/10286020.2023.2202855

By:

Meng, Yan-Qiu;
Wang, Zhi-Qi;
Li, Jin-Ming;
Xu, Dong-Ping;
Meng, Bei-Bei;
Huang, Mei-Qi

Publication type:

Article

Axitinib and sorafenib treatment inhibits high-grade glioma cell growth in vitro.

Published in:

Oncolog-Hematolog, 2023, n. 64, p. 28

By:

Artene, Ştefan-Alexandru;
Opriţa, Alexandru;
Dobrescu, Mihaela-Amelia;
Manea, Elena-Victoria;
Popescu, Ştefana-Oana;
Artene, Elena-Luiza;
Pîrvu, Andreea-Silvia;
Buzatu, Iuliana-Mihaela;
Tache, Daniela-Elise;
Dricu, Anica

Publication type:

Article

Sorafenib for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis: a systematic review of comparative studies.

Published in:

Gastroenterology Review / Przegląd Gastroenterologiczny, 2015, v. 10, n. 3, p. 142, doi. 10.5114/pg.2015.52470

By:

Xingshun Qi;
Xiaozhong Guo

Publication type:

Article

Facile fabrication of combination delivery of kaempferol and sorafenib with PEGylated gold nanoparticles delivery to breast cancer: Investigation of cytotoxicity and apoptosis induction.

Published in:

Journal of Macromolecular Science: Pure & Applied Chemistry, 2023, v. 60, n. 9, p. 628, doi. 10.1080/10601325.2023.2240824

By:

Zhang, Yunxin;
Liu, Jiange

Publication type:

Article

A Pharmacokinetic Interaction Study of Sorafenib and Iced Teas in Rats Using UPLC-MS/MS: An Illustration of Beverage-Drug Interaction.

Published in:

BioMed Research International, 2019, p. 1, doi. 10.1155/2019/2410845

By:

Maher, Hadir M.;
Almomen, Aliyah;
Alzoman, Nourah Z.;
Shehata, Shereen M.;
Al-Subaie, Amal

Publication type:

Article

Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study.

Published in:

BioMed Research International, 2019, p. 1, doi. 10.1155/2019/2141859

By:

Yuan, Jia;
Yin, Xin;
Tang, Bei;
Ma, Hui;
Zhang, Lan;
Li, Lixin;
Chen, Rongxin;
Xie, Xiaoying;
Ren, Zhenggang

Publication type:

Article

Adverse Reactions to Anticancer Drugs in the Oral Cavity.

Published in:

BioMed Research International, 2018, v. 2018, p. 1, doi. 10.1155/2018/1372874

By:

Di Fede, Olga;
Yarom, Noam;
Bagan, Jose;
Otto, Sven;
Fedele, Stefano

Publication type:

Article

Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells.

Published in:

Cancer Biology & Medicine, 2022, v. 19, n. 7, p. 1061, doi. 10.20892/j.issn.2095-3941.2021.0598

By:

Leyi Yao;
Qian Zhao;
Ding Yan;
Ziying Lei;
Yali Hao;
Jinghong Chen;
Qian Xue;
Xiaofen Li;
Qingtian Huang;
Daolin Tang;
Dou, Q. Ping;
Xin Chen;
Jinbao Liu

Publication type:

Article

A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer.

Published in:

Cancer Biology & Medicine, 2022, v. 19, n. 2, p. 136, doi. 10.20892/j.issn.2095-3941.2021.0520

By:

Yuchen Guo;
Yangyang Zhou;
Wenxin Qin

Publication type:

Article

Sorafenib induces pigmentation via the regulation of β‐catenin signalling pathway in melanoma cells.

Published in:

Experimental Dermatology, 2022, v. 31, n. 1, p. 57, doi. 10.1111/exd.14112

By:

Kim, Kyung‐Il;
Jung, Kyung Eun;
Shin, Young‐Bin;
Kim, Chang‐Deok;
Yoon, Tae‐Jin

Publication type:

Article

Fostering a healthy culture: Biological relevance of in vitro and ex vivo skin models.

Published in:

Experimental Dermatology, 2021, v. 30, n. 3, p. 298, doi. 10.1111/exd.14296

By:

Atwood, Scott X.;
Plikus, Maksim V.

Publication type:

Article

Sorafenib‐induced erythema annulare centrifugum with spontaneous resolution after skin biopsy.

Published in:

2018

By:

Yao, Chun‐An

Publication type:

Letter to the Editor

Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis.

Published in:

Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-56335-4

By:

She, Xianhua;
Yin, Donghong;
Guo, Qian;
Tang, Yang;
Wang, Shuyun;
Wang, Xuyan

Publication type:

Article

Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-43486-z

By:

Mortensen, Anja Charlotte Lundgren;
Berglund, Hanna;
Hariri, Mehran;
Papalanis, Eleftherios;
Malmberg, Christer;
Spiegelberg, Diana

Publication type:

Article

Assessing the effectiveness of camrelizumab plus apatinib versus sorafenib for the treatment of primary liver cancer: a single-center retrospective study.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-40030-x

By:

Chen, Dongbo;
Wang, Yichun;
Chen, Xiangxun;
Kang, Mei;
Zhu, Liyang

Publication type:

Article

Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-40832-z

By:

El-Hazek, Reham M. M.;
Zaher, Nashwa H.;
El-Gazzar, Mostafa G. M.;
Fadel, Noha A.;
El-Sabbagh, Walaa A.

Publication type:

Article

Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-43486-z

By:

Mortensen, Anja Charlotte Lundgren;
Berglund, Hanna;
Hariri, Mehran;
Papalanis, Eleftherios;
Malmberg, Christer;
Spiegelberg, Diana

Publication type:

Article

Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-40832-z

By:

El-Hazek, Reham M. M.;
Zaher, Nashwa H.;
El-Gazzar, Mostafa G. M.;
Fadel, Noha A.;
El-Sabbagh, Walaa A.

Publication type:

Article

Fabrication and characterization of nanodelivery platform based on chitosan to improve the anticancer outcome of sorafenib in hepatocellular carcinoma.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-38054-4

By:

Albalawi, Fahad;
Hussein, Mohd Zobir;
Fakurazi, Sharida;
Masarudin, Mas Jaffri

Publication type:

Article

Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma.

Published in:: Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2023.1354581
Publication type:: Article

Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma.

Published in:

Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2023.1124214

By:

Leineweber, Can G.;
Rabehl, Miriam;
Pietzner, Anne;
Rohwer, Nadine;
Rothe, Michael;
Pech, Maciej;
Sangro, Bruno;
Sharma, Rohini;
Verslype, Chris;
Basu, Bristi;
Sengel, Christian;
Ricke, Jens;
Schebb, Nils Helge;
Weylandt, Karsten-H.;
Benckert, Julia

Publication type:

Article

Psychiatric adverse reactions to non-selective RET multi-kinase inhibitors: a large-scale pharmacovigilance analysis.

Published in:

Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1209933

By:

Xuyan Wang;
Donghong Yin;
Yang Tang;
Feng Xiao;
Shuyun Wang

Publication type:

Article